A prospective, multicenter, randomized, double-blind placebo-controlled trial on purified and specific Cytoplasmic pollen extract for hot flashes in breast cancer survivors

References

• Runowicz CD, Leach CR, Henry NL, et al. American cancer society/American society of clinical oncology breast cancer survivorship care guideline. J Clin Oncol. 2016;34(6):611–635. doi:10.1200/JCO.2015.64.3809.
   PubMed Web of Science ®Google Scholar
• Rosso R, D'Alonzo M, Bounous VE, et al. Adherence to adjuvant endocrine therapy in breast cancer patients. Curr Oncol. 2023;30(2):1461–1472. doi:10.3390/curroncol30020112.
   PubMed Web of Science ®Google Scholar
• The 2022 hormone therapy position statement of the North American menopause society. Menopause. 2022;29(7):767–794.
   PubMed Web of Science ®Google Scholar
• The North American menopause society. The 2023 nonhormone therapy position statement of the North American menopause society. Menopause. 2023;30(6):573–590.
   PubMed Web of Science ®Google Scholar
• Biglia N, Bounous VE, De Seta F, et al. Non-hormonal strategies for managing menopausal symptoms in cancer survivors: an update. Ecancermedicalscience. 2019;13:909. doi:10.3332/ecancer.2019.909.
   PubMed Web of Science ®Google Scholar
• Simon JA, Anderson RA, Ballantyne E, et al. Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1). Menopause. 2023;30(3):239–246. doi:10.1097/GME.0000000000002138.
   PubMed Web of Science ®Google Scholar
• Trower M, Anderson RA, Ballantyne E, et al. Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial. Menopause. 2020;27(5):498–505. doi:10.1097/GME.0000000000001500.
   PubMed Web of Science ®Google Scholar
• Orleans RJ, Li L, Kim MJ, et al. FDA approval of paroxetine for menopausal hot flushes. N Engl J Med. 2014;370(19):1777–1779. doi:10.1056/NEJMp1402080.
   PubMed Web of Science ®Google Scholar
• https://www.fda.gov/news-events/press-announcements/fda-approves-novel-drug-treat-moderate-severe-hot-flashes-caused-menopause. (published on line on May 12, 2023; accessed on November 15, 2023).
   Google Scholar
• Lello S, Paris I, Cagnacci A, et al. Vasomotor symptoms and management of women undergoing treatment for breast cancer: literature review with focus on the therapeutic potential of cytoplasmic pollen extract. Gynecol Endocrinol. 2023;39(1):2162035. doi:10.1080/09513590.2022.2162035.
   PubMed Web of Science ®Google Scholar
• Biglia N, Giorgi M, Rosso R, et al. Purified and specific cytoplasmic pollen extract for the treatment of vasomotor menopausal symptoms: a review. GREM Gynecol Reprod Endocrinol Metab. 2022;3(2–3):84–87.
   Google Scholar
• Genazzani A, Panay N, Simoncini T, et al. Purified and specific cytoplasmic pollen extract: a nonhormonal alternative for the treatment of menopausal symptoms. Gynecol Endocrinol. 2020;36(3):190–196. doi:10.1080/09513590.2020.1722994.
   PubMed Web of Science ®Google Scholar
• Appel K, Veit J, Diaz P, et al. Purified and specific cytoplasmic pollen extract, PureCyTonin®, inhibits serotonin reuptake in the rat brain model. GREM Gynecol Reprod Endocrinol Metab. 2020;01(2020):64–68.
   Google Scholar
• Goldstein SR, Espié M, Druckmann R. Does purified Swedish pollen extract, a nonhormonal treatment for vasomotor symptoms, inhibit the CYP2D6 enzyme system? Menopause. 2015;22(11):1212–1214. doi:10.1097/GME.0000000000000535.
   PubMed Web of Science ®Google Scholar
• Hellström AC, Muntzing J. The pollen extract femal-a nonestrogenic alternative to hormone therapy in women with menopausal symptoms. Menopause. 2012;19(7):825–829. doi:10.1097/gme.0b013e31824017bc.
   PubMed Web of Science ®Google Scholar
• Seeger H, Ruan X, Neubauer H, et al. Membrane-initiated effects of Serelys® on proliferation and apoptosis of human breast cancer cells. Gynecol Endocrinol. 2018;34(4):353–356. doi:10.1080/09513590.2017.1407751.
   PubMed Web of Science ®Google Scholar
• Winther K, Rein E, Hedman C. Femal, a herbal remedy made from pollen extracts, reduces hot flushes and improves quality of life in menopausal women: a randomized, placebo-controlled, parallel study. Climacteric. 2005;8(2):162–170. doi:10.1080/13697130500117987.
   PubMed Web of Science ®Google Scholar
• Lello S, Capozzi A, Xholli A, et al. on behalf of the Italian Society of Menopause (SIM) and Italian Society of Gynecology of the Third Age of Women (SIGiTE). The benefits of purified cytoplasm of pollen in reducing menopausal symptoms in peri- and post-menopause: an Italian multicentre prospective observational study. Minerva Obstet Gynecol. 2022;74(6):516–521.
   PubMedGoogle Scholar
• Fait T, Sailer M, Regidor PA. Prospective observational study to evaluate the efficacy and safety of the pollen extract Sérélys® in the management of women with menopausal symptoms. Gynecol Endocrinol. 2019;35(4):360–363. doi:10.1080/09513590.2018.1538347.
   PubMed Web of Science ®Google Scholar
• Iop A, Driol P, Zacchia A, et al. Cytoplasmic pollen extract for treatment of menopausal symptoms in breast cancer patients: a case series report. Eur J Gynaecol Oncol. 2021;42(1):45–49.
   Web of Science ®Google Scholar
• Sloan JA, Loprinzi CL, Novotny PJ, et al. Methodologic lessons learned from hot flash studies. J Clin Oncol. 2001;19(23):4280–4290. doi:10.1200/JCO.2001.19.23.4280.
   PubMed Web of Science ®Google Scholar
• Schneider HP, Heinemann LA, Rosemeier HP, et al. The menopause rating scale (MRS): reliability of scores of menopausal complaints. Climacteric. 2000;3(1):59–64. doi:10.3109/13697130009167600.
   PubMedGoogle Scholar
• Buysse DJ, Reynolds CF, 3rd, Monk TH, et al. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213. doi:10.1016/0165-1781(89)90047-4.
   PubMed Web of Science ®Google Scholar
• Dama M, Mahoney JL, Van Lieshout RJ, et al. The menopause visual analogue scale: a new tool for measuring the severity and response to treatment of symptoms throughout the menopausal transition. Climacteric. 2018;21(5):502–508. doi:10.1080/13697137.2018.1495705.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. doi:10.3322/caac.21763.
   PubMed Web of Science ®Google Scholar
• Ferreira AR, Di Meglio A, Pistilli B, et al. Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis. Ann Oncol. 2019;30(11):1784–1795. doi:10.1093/annonc/mdz298.
   PubMed Web of Science ®Google Scholar
• Cucciniello L, Garufi G, Di Rienzo R, et al. Estrogen deprivation effects of endocrine therapy in breast cancer patients: incidence, management and outcome. Cancer Treat Rev. 2023;120:102624. doi:10.1016/j.ctrv.2023.102624.
   PubMed Web of Science ®Google Scholar
• Yussof I, Mohd Tahir NA, Hatah E, et al. Factors influencing five-year adherence to adjuvant endocrine therapy in breast cancer patients: a systematic review. Breast. 2022;62:22–35. doi:10.1016/j.breast.2022.01.012.
   PubMed Web of Science ®Google Scholar
• Rada G, Capurro D, Pantoja T, et al. Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Syst Rev. 2010;9:CD004923.
   PubMed Web of Science ®Google Scholar
• Cramer H, Lauche R, Klose P, et al. Yoga for improving health-related quality of life, mental health and cancer-related symptoms in women diagnosed with breast cancer. Cochrane Database Syst Rev. 2017;1(1):CD010802.
   PubMedGoogle Scholar
• Cazzaniga ME, Giordano M, Bandera M, et al. Managing menopausal symptoms in young women with breast cancer: when medicine is not all. The take care project. Clin Breast Cancer. 2021;21(5):e547–e560. doi:10.1016/j.clbc.2021.01.010.
   PubMed Web of Science ®Google Scholar
• Sanft T, Day A, Ansbaugh S, et al. NCCN guidelines insights: survivorship, version 1.2023. J Natl Compr Canc Netw. 2023;21(8):792–803. doi:10.6004/jnccn.2023.0041.
   PubMed Web of Science ®Google Scholar
• Elia D, Mares P. Evaluation de la tolérance et de l’efficacité d’un complément alimentaire Sérélys (Femal) chez les femmes en periode de ménopause. Génésis. 2008;135:12–15.
   Google Scholar
• Miyazaki K, Kaneko M, Narukawa M. Factors associated with high placebo response in clinical studies of hot flashes: a meta-analysis. Menopause. 2021;29(2):239–246. doi:10.1097/GME.0000000000001895.
   PubMed Web of Science ®Google Scholar
• Alfano CM, Lichstein KL, Vander Wal GS, et al. Sleep duration change across breast cancer survivorship: associations with symptoms and health-related quality of life. Breast Cancer Res Treat. 2011;130(1):243–254. doi:10.1007/s10549-011-1530-2.
   PubMed Web of Science ®Google Scholar
• De Franciscis P, Conte A, Schiattarella A, et al. Non-hormonal treatments for menopausal symptoms and sleep disturbances: a comparison between purified pollen extracts and soy isoflavones. Curr Pharm Des. 2020;26(35):4509–4514. doi:10.2174/1381612826666200721002022.
   PubMed Web of Science ®Google Scholar
• Chen WY, Giobbie-Hurder A, Gantman K, et al. A randomized, placebo-controlled trial of melatonin on breast cancer survivors: impact on sleep, mood, and hot flashes. Breast Cancer Res Treat. 2014;145(2):381–388. doi:10.1007/s10549-014-2944-4.
   PubMed Web of Science ®Google Scholar
• Park H, Parker GL, Boardman CH, et al. A pilot phase II trial of magnesium supplements to reduce menopausal hot flashes in breast cancer patients. Support Care Cancer. 2011;19(6):859–863. doi:10.1007/s00520-011-1099-7.
   PubMed Web of Science ®Google Scholar
• Juurlink D. Revisiting the drug interaction between tamoxifen and SSRI antidepressants. BMJ. 2016;354:i5309. doi:10.1136/bmj.i5309.
   PubMed Web of Science ®Google Scholar